30.93
-0.27(-0.87%)
Currency In USD
| Previous Close | 31.2 |
| Open | 30.81 |
| Day High | 31.01 |
| Day Low | 30.23 |
| 52-Week High | 42.29 |
| 52-Week Low | 28.39 |
| Volume | 356,066 |
| Average Volume | 474,068 |
| Market Cap | 997.5M |
| PE | 13.22 |
| EPS | 2.34 |
| Moving Average 50 Days | 30.95 |
| Moving Average 200 Days | 34.02 |
| Change | -0.27 |
If you invested $1000 in Collegium Pharmaceutical, Inc. (COLL) since IPO date, it would be worth $2,516.68 as of February 05, 2025 at a share price of $30.93. Whereas If you bought $1000 worth of Collegium Pharmaceutical, Inc. (COLL) shares 5 years ago, it would be worth $1,449.39 as of February 05, 2025 at a share price of $30.93.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Collegium Provides 2025 Financial Guidance and Business Update
GlobeNewswire Inc.
Jan 08, 2025 1:00 PM GMT
– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million – – Adjusted Operating Expens
Collegium to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 12, 2024 1:00 PM GMT
STOUGHTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today anno
Collegium Reports Record Third Quarter 2024 Financial Results
GlobeNewswire Inc.
Nov 07, 2024 9:02 PM GMT
– Generated Record Q3’24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca® Revenue of $53.2 Million and Record Xtampza® ER Revenue of $49.5 Million – – Achieved Q3’24 GAAP Net Income of $9.3 Million – – Delivered Record